Skip to main content

Advertisement

Table 5 “Risk” of OSA with respect to HIV disease characteristics

From: Likelihood of obstructive sleep apnea in people living with HIV in Cameroon – preliminary findings

  OSA 2 sided sig. of difference Entire HIV+ sample
No “risk” of OSA “Risk” of OSA
N % N %   N %
HIV genotype
 HIV1 8 42.1 5 31.3 0.679 13 37.1
 HIV2 1 5.3 2 12.5 3 8.6
 HIV1+2 0 0.0 1 6.3 1 2.9
Undetermined genotype 10 52.6 8 50.0 18 51.4
Age at diagnosis (years)
Mean ± SD 34.55 ± 9.84 37.24 ± 10.51 0.416 34.27 ± 9.29
 20–24 6 28.6 3 17.6 0.425 9 23.7
 ≥25 15 71.4 14 82.4 29 76.3
Duration since diagnosis
 <= 6 months 8 38.1 6 35.3 0.717 14 36.8
 >6 months 13 61.9 11 64.7 24 63.2
CD4 count (count/mm3)
 Mean ± SD 387.10 ± 150.58 490.33 ± 107.96 0.299 410.92 ± 144.90
  <350 3 30.0 0 0.0 0.528 3 23.1
  ≥350 7 70.0 3 100.0 10 76.9
WHO disease stage
 Stage 1 15 71.4 11 64.7 0.930 26 68.4
 Stage 2 2 9.5 1 5.9 3 7.9
 Stages 3–4 4 19.1 5 29.4 9 23.7
Routine check-ups in last 3 months
 None 10 50.0 10 58.8 0.591 20 54.1
 At least 1 10 50.0 7 41.2 17 45.9
Patient on HAART
 Yes 8 38.1 6 35.3 1.00 14 36.8
 No 13 61.9 11 64.7 24 63.2
HAART duration
Mean ± SD 61.11 ± 51.59 32.75 ± 32.27 0.201 47.76 ± 44.71
 <6 months 2 22.2 2 25.0 1.00 4 23.5
 ≥6 months 7 77.8 6 75.0 13 76.5
HAART protocols   0.0     0  
 1st line 8 100.0 5 83.3 0.429 13 92.9
 2nd line 0 0.0 1 16.7 1 7.1
Compliance last 30 days
 Compliant 4 40.0 6 100.0 0.034 a 10 62.5
 Not complaint 6 60.0 0 0.0 6 37.5
Complications in last 3 months
 None 0 0.0 2 11.8 0.204 2 5.4
 At least one 20 100.0 15 88.2 35 94.
Presence of other concurrent diseases
 At least one 2 10.0 3 17.6 0.644 5 13.5
 None 18 90.0 14 82.4 32 86.5
  1. asignificant difference. OSA Obstructive Sleep Apnea